# HURON study Chronic Uveitis evaluation of the Intravitreal Dexamethasone Implant * Study Questions : efficacy and safety of the injectable dexamethasone intravitreal implant at 2 doses (0.35 mg and 0.70 mg) compared to placebo (sham) * primary endpoint: vitreous haze grade 0 * Ozurdex group more likely than the sham group to have vitreous haze grade of 0 at 8 weeks * <5% of eyes developed IOp ≥35 mm hg and <10% had IOp ≥25 mm hg. * Cataracts developed in 15%